Invivyd unveils preclinical data for measles antibody VMS063
Invivyd presented early‑stage data on VMS063, a monoclonal antibody that blocks the measles fusion protein, showing strong laboratory activity against current B3 and D8 virus strains. The company said it will increase manufacturing capacity to support first‑in‑human trials slated for 2027. No FDA‑approved measles therapies exist, and U.S. case numbers have risen to roughly twice the 2025 level.
Why it matters
The announcement marks the first R&D milestone for Invivyd’s entry into the measles market, potentially creating a new revenue stream if the antibody receives approval. Investors should watch for upcoming IND filing and clinical trial funding requirements.
Key facts
- 1VMS063 targets the measles fusion (F) protein and is engineered to lock it in a pre‑fusion state, preventing viral entry. stocktitan.net
- 2In laboratory assays the antibody neutralized both authentic virus and pseudovirus forms of the B3 and D8 genotypes. stocktitan.net
- 3Invivyd has begun to expand manufacturing with the aim of initiating clinical development in 2027. tradingview.com
- 4The United States is seeing a record‑high measles surge in 2026, with disease burden nearly double that of 2025. investing.com
- 5There are currently no FDA‑approved treatments for measles. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.